Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: Age, mediastinal downstaging, and extent of pulmonary resection as independent predictors

被引:40
|
作者
Paul, Subroto [1 ]
Mirza, Farooq [1 ]
Port, Jeffrey L. [1 ]
Lee, Paul C. [1 ]
Stiles, Brendon M. [1 ]
Kansler, Amanda L. [1 ]
Altorki, Nasser K. [1 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Thorac Surg, Dept Cardiothorac Surg, New York, NY 10065 USA
来源
关键词
RANDOMIZED CONTROLLED-TRIAL; COMPARING PERIOPERATIVE CHEMOTHERAPY; HIGH-DOSE RADIATION; PREOPERATIVE CHEMOTHERAPY; SURGICAL RESECTION; NEOADJUVANT THERAPY; PHASE-III; FOLLOW-UP; NODES N2; SURGERY;
D O I
10.1016/j.jtcvs.2010.07.092
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In clinical stage IIIA non-small cell lung cancer, the role of surgical resection, particularly pneumonectomy, after induction therapy remains controversial. Our objective was to determine factors predictive of survival after postinduction surgical resection. Methods: We retrospectively reviewed a prospectively collected database of 136 patients who underwent surgical resection after induction chemotherapy (n = 119) or chemoradiation (n = 17) from June 1990 to January 2010. Results: One hundred five lobectomies or bilobectomies and 31 pneumonectomies were performed. There was 1 perioperative death (pneumonectomy). Seventy-one patients had downstaging to N0 or N1 nodal status (52%). There were 2 complete pathologic responses. Median follow-up was 42 months (range, 0.69-136 months). Overall 5-year survival for entire cohort was 33% (36% lobectomy, 22% pneumonectomy, P = .001). Patients with pathologic downstaging to pN0 or pN1 had improved 5-year survival (45% vs 20%, P = .003). For patients with pN0 or pN1 disease, survival after lobectomy was better than after pneumonectomy (48% vs 27%, P = .011). In patients with residual N2 disease, there was no statistically significant survival difference between lobectomy and pneumonectomy (5-year survival, 21% vs 19%; P = .136). Multivariate analysis showed as independent predictors of survival age (hazard ratio, 1.05; P = .002), extent of resection (hazard ratio, 2.01; P = .026), and presence of residual pN2 (hazard ratio, 1.60; P = .047). Conclusions: After induction therapy for patients with clinical stage IIIA disease, both pneumonectomy and lobectomy can be safely performed. Although survival after lobectomy is better, long-term survival can be accomplished after pneumonectomy for appropriately selected patients. Nodal downstaging is important determinant of survival, particularly after lobectomy. (J Thorac Cardiovasc Surg 2011;141:48-58)
引用
收藏
页码:48 / 58
页数:11
相关论文
共 50 条
  • [21] Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal Downstaging After Induction Chemotherapy and Surgery
    Amini, Arya
    Lou, Feiran
    Correa, Arlene M.
    Baldassarre, Randall
    Rimner, Andreas
    Huang, James
    Roth, Jack A.
    Swisher, Stephen G.
    Vaporciyan, Ara A.
    Lin, Steven H.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (06) : 1934 - 1940
  • [22] Predictors of Survival in Patients With Non-Small Cell Lung Cancer
    Luo, Juhua
    Chen, Yea-Jyh
    Narsavage, Georgia L.
    Ducatman, Alan
    ONCOLOGY NURSING FORUM, 2012, 39 (06) : 609 - 616
  • [23] Predictors of Recurrence after Curative Resection in Patients with Early-Stage Non-Small Cell Lung Cancer
    Lee, Sang Hee
    Jo, Eun Jung
    Eom, Jung Seop
    Mok, Jeong Ha
    Kim, Mi Hyun
    Lee, Kwangha
    Kim, Ki Uk
    Park, Hye-Kyung
    Lee, Chang Hun
    Kim, Yeong Dae
    Lee, Min Ki
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2015, 78 (04) : 341 - 348
  • [24] Building a better therapy for stage IIIA non-small cell lung cancer
    Evans, TL
    Donahue, DM
    Mathisen, DJ
    Lynch, TJ
    CLINICS IN CHEST MEDICINE, 2002, 23 (01) : 191 - +
  • [25] CLINICAL PREDICTORS OF MEDIASTINAL METASTASIS IN PATIENTS WITH SURGICALLY RESECTABLE NON-SMALL CELL LUNG CANCER
    Lyons, Gustavo A.
    Quadrelli, Silvia
    Silva, Carlos
    Chimondeguy, Domingo J.
    Lescano, Matias
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S857 - S858
  • [26] The prognosis of clinical stage IIIa non-small cell lung cancer in Taiwan
    Cheng, Ya-Fu
    Huang, Jing-Yang
    Lin, Ching-Hsiung
    Wang, Bing-Yen
    CANCER MEDICINE, 2023, 12 (16): : 17087 - 17097
  • [27] Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935
    Jaklitsch, Michael T.
    Herndon, James E., II
    Decamp, Malcolm M., Jr.
    Richards, William G.
    Kumar, Parvesh
    Krasna, Mark J.
    Green, Mark R.
    Sugarbaker, David J.
    JOURNAL OF SURGICAL ONCOLOGY, 2006, 94 (07) : 599 - 606
  • [28] Extent of Removal for Mediastinal Nodal Stations for Patients with Clinical Stage I Non-Small Cell Lung Cancer: Effect on Outcome
    Jeon, Hyun Woo
    Moon, Mi Hyung
    Kim, Kyung Soo
    Du Kim, Young
    Wang, Young Pil
    Park, Hyung Joo
    Park, Jae Kil
    THORACIC AND CARDIOVASCULAR SURGEON, 2014, 62 (07): : 599 - 604
  • [29] Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands
    Joosten, Pieter J. M.
    Damhuis, Ronald A. M.
    van Diessen, Judi N. A.
    de Langen, Joop A.
    Belderbos, Jose S. A.
    Smit, Egbert F.
    Klomp, Houke M.
    Veenhof, Alexander A. F. A.
    Hartemink, Koen J.
    ACTA ONCOLOGICA, 2020, 59 (07) : 748 - 752
  • [30] Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer
    Jeremic, B
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (02): : 444 - 445